Which companies overlap with Mantecorp Industria Quimica e Farmaceutica Ltd.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mantecorp-industria-quimica-e-farmaceutica-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mantecorp Industria Quimica e Farmaceutica Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mantecorp Industria Quimica e Farmaceutica Ltd. pipeline: 1 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ibuprofen, dipyrone, acetaminophen	ibuprofen, dipyrone, acetaminophen	marketed
Ibuprofen plus caffeine	Ibuprofen plus caffeine	phase 3	NSAID with adjuvant analgesic	COX-1, COX-2; adenosine receptors	Pain Management
Dexchlorpheniramine, pseudoephedrine, guaifenesin	Dexchlorpheniramine, pseudoephedrine, guaifenesin	phase 3	Antihistamine/decongestant/expectorant combination	H1 receptor (dexchlorpheniramine); alpha-1 adrenergic receptor (pseudoephedrine)	Respiratory/Allergy
Dexchlorpheniramine 1% lotion	Dexchlorpheniramine 1% lotion	phase 3	H1-receptor antagonist (first-generation antihistamine)	H1 histamine receptor	Dermatology / Allergy
Glucosamine sulfate + chondroitin sulfate - CONDROFLEX	Glucosamine sulfate + chondroitin sulfate - CONDROFLEX	phase 3	Nutraceutical/Chondroprotective agent		Rheumatology/Orthopedics
Dexchlorpheniramine 1% gel	Dexchlorpheniramine 1% gel	phase 3	H1-receptor antagonist (first-generation antihistamine)	H1 histamine receptor	Dermatology / Allergy
Glucosamine sulfate + chondroitin sulfate - MANTECORP	Glucosamine sulfate + chondroitin sulfate - MANTECORP	phase 3	Symptomatic slow-acting drug in osteoarthritis (SYSADOA)		Rheumatology / Orthopedics

Therapeutic area mix

Dermatology / Allergy · 2
Pain Management · 1
Respiratory/Allergy · 1
Rheumatology / Orthopedics · 1
Rheumatology/Orthopedics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Mantecorp Industria Quimica e Farmaceutica Ltd.:

Cite this brief

Drug Landscape (2026). Mantecorp Industria Quimica e Farmaceutica Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mantecorp-industria-quimica-e-farmaceutica-ltd. Accessed 2026-05-17.